Tower Research Capital LLC TRC Takes Position in KALA BIO, Inc. (NASDAQ:KALA)

Tower Research Capital LLC TRC acquired a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned approximately 0.16% of KALA BIO as of its most recent SEC filing.

Separately, Knights of Columbus Asset Advisors LLC increased its holdings in shares of KALA BIO by 100.0% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 4,834 shares of the company’s stock valued at $34,000 after acquiring an additional 2,417 shares in the last quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on KALA. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a report on Monday, April 1st. HC Wainwright decreased their price target on KALA BIO from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.

KALA BIO Stock Up 3.7 %

KALA BIO stock traded up $0.25 during trading on Friday, hitting $7.01. 4,531 shares of the company were exchanged, compared to its average volume of 11,435. The business’s 50 day moving average is $7.34 and its 200 day moving average is $7.11. KALA BIO, Inc. has a 52 week low of $5.10 and a 52 week high of $19.35. The company has a market capitalization of $19.73 million, a P/E ratio of -0.39 and a beta of -1.75. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 5.10.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Friday, March 29th. The company reported ($3.18) earnings per share (EPS) for the quarter. Analysts predict that KALA BIO, Inc. will post -11.28 earnings per share for the current year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.